Generic Cancer Treatment Approved by FDA for 2026

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.

Furthermore, the company has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for lenalidomide capsules in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths.

Availability will begin Jan. 31, 2026.